Medical insurance reimbursement policy for sparsentan/sparsentan

Sparsentan/Sparsentan is a new dual endothelin and angiotensin receptor antagonist mainly used to treat primary IgA nephropathy (IgAN). IgAN is a common glomerular disease characterized by the deposition of IgA in the renal tubules, leading to a gradual deterioration of the patient's kidney function. One of the prominent symptoms of the disease is high levels of proteinuria, a condition that is often closely associated with further decline in kidney function. Therefore, effective control of proteinuria has become an important goal in IgAN treatment.

Through its unique mechanism of action, sparsentane is able to significantly reduce protein excretion in the urine, thereby mitigating the risk of disease progression. Clinical studies have shown that sparsentan can effectively improve patients' urine protein/creatinine ratio (UPCR) and has demonstrated good safety and tolerability in clinical trials. This increases the clinical application value of sparsentane in IgAN patients, especially those patients whose urinary protein excretion exceeds 1.5g/g.

Regarding the medical insurance reimbursement policy of sparsentin, as a new drug, it usually needs to go through certain review procedures before it can be included in the scope of medical insurance reimbursement. After being launched overseas, Sparsentan received accelerated approval from the FDA, which immediately attracted the attention of insurance companies. Many companies began to evaluate the clinical efficacy and economic value of this drug to decide whether to include it in the medical insurance payment list.

Although specific reimbursement policies may vary by region and different insurance plans, generally speaking, for IgAN patients who have been diagnosed by a doctor and meet the conditions for use, insurance companies will usually provide a certain degree of reimbursement support. Patients should understand the specific reimbursement details of their insurance in advance, as well as the application materials that may be required.

Reference materials:https://ir.travere.com/news-releases/news-release-details/travere-therapeutics-announces-licensing-agreement-renalys